… these immunotherapeutic interventions and the COVID-19-associated cytokine storm syndrome…
, including clinical trials, in other cytokine storm syndrome, especially patients with critical …

… cytokines known as cytokine storm syndrome. This article reported the various checkpoints
targeted to manage the SARS-CoV-2-induced cytokine storm. The … and cytokine storm were …

… safety data, and therefore these agents are not a realistic option at the present time [20]. …
treatment (immunotherapy) has been used to manage a COVID-19 cytokine storm and although …

… potential to inhibit cytokines and treat the cytokine storm. Current mini review discuss
several immune modulators such as specific immune modulators (anti-cytokines such as IL-1and …

… of inflammatory cytokines and cytokine storm. Various underlying factors such as age, gender,
blood pressure, diabetes, and obesity affect cytokine storm. It seems that cytokine storm is …

… , and hematology to discuss further treatment options. Etoposide had previously been …
Alternative therapies were not available given the novelty of disease and limited options of …

… IL-6 values between 35 and 90 pg/ml, may therefore represent the right time to interrupt
the inflammatory cascade and prevent lethal cytokine storm. … therapeutic options to anti-cytokine …

… mechanisms sustaining the clinical course and patients-related factors driving the final
outcome will be helpful in developing effective preventive strategies and/or therapeutical options. …

… Hyper-induction of pro-inflammatory cytokines, also known as a cytokine storm or
cytokine release syndrome (CRS), is one of the key aspects of the currently ongoing SARS-CoV-2 …

… , sometimes referred to as ‘cytokine storm’. One hallmark feature of … , and are a therapeutic
option in a number of inflammatory … agents as an option to prevent or treat cytokine release in …